Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A newly engineered antibody acts like an on/off switch for IL-12, a powerful anti-tumor immune signal that has long been too toxic to use safely. The molecule stays "off" in healthy tissue but activates only inside tumors, where a specific protein called FN-EDB is present. Early lab data and computer modeling suggest this approach could dramatically improve the safety profile of IL-12-based cancer therapy.
IL-12 is one of the most potent cancer-fighting cytokines the immune system produces — but for nearly 30 years, its clinical potential has been stifled by severe systemic toxicity. Previous attempts to tame it, from localized injections to pro-drug designs, haven't cracked the problem. Now, researchers at FairJourney Bio may have found a smarter path forward.
Published in the peer-reviewed journal mAbs, the study describes a dual-specificity antibody fragment engineered to act as a reversible "logic gate." The molecule binds to IL-12 and keeps it inactive — until it encounters fibronectin-EDB (FN-EDB), a protein found specifically in the tumor microenvironment. Once there, the switch flips, releasing IL-12 activity right where it's needed and sparing healthy tissue.
Key Takeaways:
Why it matters: If this approach holds up in further studies, it could revive IL-12 as a viable cancer immunotherapy — offering potent anti-tumor activity with a far safer profile than previously possible.
